Format

Send to

Choose Destination
See comment in PubMed Commons below
Chest. 2011 Jul;140(1):91-99. doi: 10.1378/chest.10-1353. Epub 2010 Nov 24.

Midregional proatrial natriuretic peptide predicts survival in exacerbations of COPD.

Author information

1
Clinic for Pulmonary Medicine and Respiratory Cell Research, University Hospital Basel, Basel.
2
Department for Emergency Medicine, University Hospital Basel, Basel.
3
Clinic for Internal Medicine, University Hospital Basel, Basel.
4
Clinic for Internal Medicine, Hospital Aarau, Aarau, Switzerland.
5
Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Basel, Basel.
6
Clinic for Pulmonary Medicine and Respiratory Cell Research, University Hospital Basel, Basel. Electronic address: stolzd@uhbs.ch.

Abstract

BACKGROUND:

Recently, the use of systemic biomarkers to monitor and assess the clinical evolution of respiratory disease has gained interest. We investigated whether midregional proatrial natriuretic peptide (MR-proANP) predicts survival in patients with COPD when they are admitted to the hospital for exacerbation.

METHODS:

One hundred sixty-seven patients (mean age 70 years old, 75 men) admitted to the hospital for exacerbation were followed up for 2 years. MR-proANP was measured on admission, after 14 days, and at 6 months. The predictive value of clinical, functional, and laboratory parameters on admission were assessed by Cox regression analyses. The time to death was analyzed by Kaplan-Meier survival curves.

RESULTS:

MR-proANP level was significantly higher on admission for exacerbation, compared with recovery and stable state (P = .004 for the comparison among all time points). MR-proANP correlated with the Charlson condition and age-related score (P < .0001), left ventricular ejection fraction (P < .0001), C-reactive protein (P = .037), and FEV(1)% predicted (P = .004). MR-proANP levels were similar in patients requiring ICU treatment and in those treated in the medical ward (P = .086). Thirty-seven patients (22%) died within 2 years. MR-proANP levels were higher in nonsurvivors compared with survivors (median [interquartile range] 185 pmol/L [110-286] vs 92 pmol/L [56-158], P < .001). Mortality was higher across MR-proANP quartiles (log rank P < .0001). Charlson condition and age-related score (P = .001), Paco(2) (P < .0001), and MR-proANP (P = .001) predicted mortality in the univariate Cox-regression model. Both MR-proANP and Paco(2) were independent predictors of mortality in the multivariate Cox regression model.

CONCLUSIONS:

MR-proANP at exacerbation is associated with 2-year long-term survival in patients with exacerbation of COPD.

PMID:
21106656
DOI:
10.1378/chest.10-1353
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center